Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

CorMedix (CRMD) Gross Margin (2016 - 2025)

CorMedix has reported Gross Margin over the past 12 years, most recently at 83.43% for Q4 2025.

  • Quarterly results put Gross Margin at 83.43% for Q4 2025, down 1280.0% from a year ago — trailing twelve months through Dec 2025 was 88.46% (down 414.0% YoY), and the annual figure for FY2025 was 88.46%, down 420.0%.
  • Gross Margin reached 83.43% in Q4 2025 per CRMD's latest filing, down from 89.26% in the prior quarter.
  • Across five years, Gross Margin topped out at 98.63% in Q4 2022 and bottomed at 76.12% in Q2 2021.
  • Median Gross Margin over the past 4 years was 83.43% (2025), compared with a mean of 63.31%.
  • The largest annual shift saw Gross Margin plummeted -5945bps in 2021 before it soared 17456bps in 2022.
  • Over 4 years, Gross Margin stood at 14.88% in 2021, then soared by 563bps to 98.63% in 2022, then dropped by -2bps to 96.24% in 2024, then dropped by -13bps to 83.43% in 2025.
  • Business Quant data shows Gross Margin for CRMD at 83.43% in Q4 2025, 89.26% in Q3 2025, and 95.31% in Q2 2025.